Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 21

Trial Status

Completed3

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT00387751Phase 2Completed
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
PrincipalinvestigatorStart date: 2006-08-01
NCT00042809Phase 1Completed
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Principalinvestigator
NCT00255658Phase 1Completed
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Heinz-Josef Lenz, MD

University of Southern California

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Naiyer Rizvi, MD

Memorial Sloan Kettering Cancer Center

Related
9 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Scot C. Remick, MD

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Corey J. Langer, MD

Fox Chase Cancer Center

Related
16 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Gustavo Leone

Medical University of South Carolina, Hollings Cancer Center

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific
Similarity Score8%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

William I. Bensinger, MD

Fred Hutchinson Cancer Center

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Charles L. Loprinzi, MD

Mayo Clinic

Related
14 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT00387751Phase 2PrincipalInvestigator

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
Completed
NCT00042809Phase 1PrincipalInvestigator

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Completed
NCT00255658Phase 1PrincipalInvestigator

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Completed

All 3 trials loaded